# MP-AzeFlu Allergen Chamber - Onset of Action Study

> **NCT03004131** · PHASE4 · COMPLETED · sponsor: **MEDA Pharma GmbH & Co. KG** · enrollment: 82 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Azelastine hydrochloride + fluticasone propionate nasal spray
- **DRUG:** Placebos
- **DRUG:** fluticasone propionate nasal spray + loratadine

## Key facts

- **NCT ID:** NCT03004131
- **Lead sponsor:** MEDA Pharma GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-07
- **Primary completion:** 2017-03-29
- **Final completion:** 2017-03-29
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004131, "MP-AzeFlu Allergen Chamber - Onset of Action Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03004131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*